In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Chemed (CHE – Research Report), with a price target of $590.00. The company’s shares closed yesterday at $507.00.
According to TipRanks, Wiederhorn is a top 100 analyst with an average return of 14.9% and a 65.73% success rate. Wiederhorn covers the Healthcare sector, focusing on stocks such as Centene, Chemed, and Community Health.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Chemed with a $592.00 average price target, representing a 16.77% upside. In a report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $610.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
CHE market cap is currently $7.64B and has a P/E ratio of 33.81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chemed (CHE) Company Description:
Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the following segments: VITAS and Roto-Rooter. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.
Read More on CHE:
